Q4 EPS Estimate for Encompass Health Decreased by Analyst

Encompass Health Co. (NYSE:EHC) – Research analysts at Zacks Research dropped their Q4 2025 EPS estimates for Encompass Health in a research note issued to investors on Monday, November 11th. Zacks Research analyst Z. Masood now anticipates that the company will post earnings of $1.15 per share for the quarter, down from their prior forecast of $1.18. The consensus estimate for Encompass Health’s current full-year earnings is $4.29 per share. Zacks Research also issued estimates for Encompass Health’s Q1 2026 earnings at $1.35 EPS and FY2026 earnings at $5.31 EPS.

Encompass Health (NYSE:EHC) last released its quarterly earnings results on Monday, October 28th. The company reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.09. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.33 billion. Encompass Health had a net margin of 8.10% and a return on equity of 17.60%. Encompass Health’s revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.86 EPS.

A number of other research firms have also issued reports on EHC. Truist Financial reaffirmed a “buy” rating and set a $116.00 target price (up from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. Royal Bank of Canada lifted their price objective on shares of Encompass Health from $105.00 to $110.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Barclays increased their target price on shares of Encompass Health from $109.00 to $116.00 and gave the company an “overweight” rating in a research note on Tuesday, October 29th. KeyCorp lifted their price target on shares of Encompass Health from $115.00 to $117.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 29th. Finally, Stephens reiterated an “overweight” rating and set a $105.00 price objective on shares of Encompass Health in a research report on Tuesday, August 6th. Nine research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Encompass Health currently has an average rating of “Buy” and an average target price of $107.11.

Encompass Health Stock Up 0.1 %

Shares of EHC stock opened at $102.69 on Wednesday. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.04 and a current ratio of 1.04. The stock has a market cap of $10.35 billion, a PE ratio of 24.80, a price-to-earnings-growth ratio of 1.36 and a beta of 0.88. The business’s fifty day moving average is $95.90 and its 200-day moving average is $89.98. Encompass Health has a 1 year low of $63.59 and a 1 year high of $104.55.

Hedge Funds Weigh In On Encompass Health

A number of institutional investors have recently made changes to their positions in EHC. CIBC Asset Management Inc boosted its position in shares of Encompass Health by 3.5% in the third quarter. CIBC Asset Management Inc now owns 2,957 shares of the company’s stock valued at $286,000 after acquiring an additional 100 shares during the period. Commonwealth Equity Services LLC increased its holdings in shares of Encompass Health by 1.3% during the 2nd quarter. Commonwealth Equity Services LLC now owns 9,845 shares of the company’s stock worth $845,000 after purchasing an additional 123 shares during the period. V Square Quantitative Management LLC raised its position in shares of Encompass Health by 53.0% during the third quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock valued at $39,000 after buying an additional 140 shares during the last quarter. O Shaughnessy Asset Management LLC lifted its stake in shares of Encompass Health by 3.9% in the first quarter. O Shaughnessy Asset Management LLC now owns 4,246 shares of the company’s stock valued at $351,000 after buying an additional 160 shares during the period. Finally, Verdence Capital Advisors LLC grew its position in Encompass Health by 4.6% during the third quarter. Verdence Capital Advisors LLC now owns 3,670 shares of the company’s stock worth $355,000 after buying an additional 160 shares in the last quarter. 97.25% of the stock is currently owned by institutional investors.

Encompass Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd will be paid a $0.17 dividend. The ex-dividend date is Thursday, January 2nd. This represents a $0.68 dividend on an annualized basis and a yield of 0.66%. Encompass Health’s payout ratio is presently 16.43%.

Encompass Health announced that its board has initiated a share repurchase plan on Wednesday, July 24th that permits the company to buyback $500.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 5.4% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s management believes its stock is undervalued.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.